. Author manuscript; available in PMC: 2008 Mar 15.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2006 Dec 29;67(4):1074–1081. doi: 10.1016/j.ijrobp.2006.10.023

Table 3.

Univariate Analysis of Potential Predictors of Biochemical Failure and Distant Metastasis

		Biochemical Failure				Distant Metastasis
	No. of Patients (5-year)	ASTRO^*		Nadir+2^†
Predictor	No. of Patients (5-year)	(5-Year)	P	(5-Year)	P	(5-Year)	P
T-stage
T1-T2	606	37%		26%		4%
T3-T4	61	59%	.0001	45%	.002	12%	.016
Gleason score
2-6	357	48%		25%		3%
7-10	310	42%	.559	31%	.042	8%	.002
iPSA (ng/mL)
≤10	182	37%		22%		5%
>10-20	337	30%		23%		4%
>20	148	66%	<.0001	47%	<.0001	8%	.043
RT Dose (Gy)
<74	224	50%		32%		8%
74-76	270	36%		29%		4%
>76	173	30%	<.0001	18%	.040	2%	.010

Abbreviations: ASTRO = American Society of Therapeutic Radiation Oncology; iPSA = initial pretreatment prostate-specific antigen level; RT = radiotherapy; Gy = Gray.

ASTRO definition of biochemical failure: 3 consecutive rises in PSA, with BF backdated to midpoint between nadir and the first rise (16).

^†

Nadir+2 definition of biochemical failure: PSA ≥ nadir + 2ng/mL (17-21).